TERBUTALINE SULFATE tablet

Country: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

TERBUTALINE SULFATE (UNII: 576PU70Y8E) (TERBUTALINE - UNII:N8ONU3L3PG)

Fáanlegur frá:

Chartwell RX, LLC.

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Vörulýsing:

Terbutaline sulfate tablets, USP are packaged in bottles of 90 tablets. Descriptions of the 2.5 and 5 mg tablets follow: Tablets 2.5 mg—round, white, scored (imprinted LCI over 1318) Bottles of 90       NDC 62135-524-90 Tablets 5 mg—round, white, scored (imprinted LCI over 1311) Bottles of 90       NDC 62135-525-90 Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure. Manufactured for: Chartwell RX, LLC. Congers, NY 10920 L71336 Revised 02/2023

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

TERBUTALINE SULFATE- TERBUTALINE SULFATE TABLET
CHARTWELL RX, LLC.
----------
TERBUTALINE SULFATE TABLETS, USP
RX ONLY
WARNING: TOCOLYSIS
ORAL TERBUTALINE SULFATE HAS NOT BEEN APPROVED AND SHOULD NOT BE USED
FOR ACUTE OR MAINTENANCE TOCOLYSIS. IN PARTICULAR, TERBUTALINE SULFATE
SHOULD NOT BE USED FOR MAINTENANCE TOCOLYSIS IN THE OUTPATIENT OR HOME
SETTING. SERIOUS ADVERSE REACTIONS, INCLUDING DEATH, HAVE BEEN
REPORTED
AFTER ADMINISTRATION OF TERBUTALINE SULFATE TO PREGNANT WOMEN. IN THE
MOTHER, THESE ADVERSE REACTIONS INCLUDE INCREASED HEART RATE,
TRANSIENT
HYPERGLYCEMIA, HYPOKALEMIA, CARDIAC ARRHYTHMIAS, PULMONARY EDEMA AND
MYOCARDIAL ISCHEMIA. INCREASED FETAL HEART RATE AND NEONATAL
HYPOGLYCEMIA MAY OCCUR AS A RESULT OF MATERNAL ADMINISTRATION [SEE
_CONTRAINDICATIONS, TOCOLYSIS_].
DESCRIPTION
Terbutaline sulfate USP is a beta-adrenergic agonist bronchodilator
available as tablets of
2.5 mg (2.05 mg of the free base) and 5 mg (4.1 mg of the free base)
for oral
administration. Terbutaline sulfate is ±-α-[( _tert_ –butylamino)
methyl]-3,5-
dihydroxybenzyl alcohol sulfate (2:1) (salt). The molecular formula is
(C
H
NO
)
•
H
SO
and the structural formula is
Terbutaline sulfate USP is a white to gray-white crystalline powder.
It is odorless or has a
faint odor of acetic acid. It is soluble in water and in 0.1N
hydrochloric acid, slightly
soluble in methanol, and insoluble in chloroform. Its molecular weight
is 548.65.
_Inactive Ingredients:_ anhydrous lactose, pregelatinized corn starch,
microcrystalline
cellulose, povidone, and magnesium stearate.
12
19
3
2
2
4
CLINICAL PHARMACOLOGY
_In vitro _and _in vivo _pharmacologic studies have demonstrated that
terbutaline exerts a
preferential effect on beta
-adrenergic receptors. While it is recognized that beta2-
adrenergic receptors are the predominant receptors in bronchial smooth
muscle, data
indicate that there is a population of beta2-receptors in the human
heart, existing in a
concentration between 10% to 50%. The precise function of these
receptors has not
bee